-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
T-cell acute lymphoblastic leukemia (T-ALL) is a common hematological malignancy.
Although combined chemotherapy has greatly changed the efficacy of T-ALL, 20% of children and 50% of adults still die from this disease
.
The identification of T-ALL driver genes and abnormal signaling pathways will promote the understanding of its pathological mechanism and provide an important
In this study, 47 high-frequency driver gene mutations and 156 gene fusions were detected in 165 samples
.
Combining transcriptional profiles and gene fusion information, we divided T-ALL into four subtypes, LOM2/LYL1, HOXA, TLX, and TAL, and studied the mutational preferences of different molecular subtypes
Wu Hong, Zhu Xiaofan, Huang Xiaojun and Zhang Leping are the co-corresponding authors of this paper
.
Dr.
Zhu Haichuan (currently working at Wuhan University of Science and Technology), a doctoral student who has graduated from Wu Hong's laboratory, Dong Bingjie, a doctoral student, and Zhang Yingchi, associate researcher of the Hematology Hospital (Institute of Hematology), Chinese Academy of Medical Sciences, are the co-first authors of this article
Top: Clinical factors and mutation information related to survival; Bottom left: Correlation of RAS signaling pathway mutations in non-TAL subtypes with patient prognosis; Bottom right: Correlation of PTEN mutations in TAL subtypes with patient prognosis
